Eprosartan - a novel angiotensin II receptor antagonist with sympathoinhibitory activity. Clinical efficacy and safety in arterial hypertension

Eprosartan is the only nonbiphenyl, nontetrazole competitive angiotensin II receptor antagonist available and is high selective for the AT(1)-receptor subtype. Eprosartan also has sympathoinhibitory activity as demonstrated b y an inhibition of presser responses induced by activation of sympathetic o utflow through spinal cord stimulation in pithed rats. In clinical trials e prosartan has been shown to lower blood pressure effectively in once-daily regimen in hypertensive patients. In recommended dose range (600-800 mg onc e daily) eprosartan is effective in patients with ail grades of hypertensio n, regardless of age, sex, or race. Tolerability of eprosartan has been sho wn to be superior to ACE inhibitors and comparable to placebo.